CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL, an Asahi Kasei company, has been selected to exhibit SuperSaturated Oxygen (SSO 2) Therapy, which delivers high levels of dissolved oxygen directly to the ...

Important Milestone Toward Bringing SSO 2 Therapy to the U.S. Market Simon Dixon, MBChB, chair of cardiovascular medicine at Beaumont Hospital Royal Oak and an investigator for this study, noted, “In ...

Newark Beth Israel Medical Center, an RWJBarnabas Health facility, now offers heart attack patients a minimally invasive, “cutting-edge” cardiac treatment. The health care provider announced Nov. 29 ...

CHELMSFORD, Mass., October 31, 2022--(BUSINESS WIRE)--ZOLL, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that its TherOx SuperSaturated ...

TherOx Inc., an Irvine-based medical device maker in business for more than 20 years and with more than $150 million invested in it over its history, has been acquired, two months after the company ...

IRVINE, Calif.--(BUSINESS WIRE)--TherOx, Inc., a privately held medical device company focused on improving treatment of Acute Myocardial Infarction (AMI), announced that the U.S. Food and Drug ...

Henry Mayo Newhall Hospital is one of the first hospitals in Southern California to improve treatment of "widowmaker" heart ...

ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that the Centers for Medicare & Medicaid Services (CMS) ICD-10 Coordination ...

The Category III CPT code for SSO 2 Therapy was supported by the leadership of the Society for Cardiac Angiography and Interventions (SCAI) and the American College of Cardiology (ACC). The decision ...

Fresh off receiving a PMA, TherOx is now in the process of being acquired by Zoll Medical, an Asahi Kasei Group Company. Additional terms of the deal were not disclosed. Irvine, CA-based TherOX is ...